Denmark-based clinical-stage biotech company NMD Pharma A/S announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application to initiate a Phase 2 trial (SYNAPSE-CMT) of NMD670, a first-in-class muscle-targeted therapy, in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.
The randomised, double-blind, placebo-controlled trial will assess the safety, efficacy and tolerability of NMD670 in around 80 adult patients across the United States and Europe. Expected to begin enrolment soon, the 21-day trial will evaluate endpoints including 6-minute walk test and timed-up-and-go test.
This follows NMD Pharma's announcement of positive results from the ESTABLISH study in June 2023, highlighting neuromuscular junction dysfunction as a characteristic in CMT patients.
SYNAPSE-CMT joins two ongoing Phase 2 trials of NMD670 for spinal muscular atrophy (SMA) type 3 and generalised myasthenia gravis, solidifying NMD Pharma's focus on rare neuromuscular diseases.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD